Vicore Highlights the P-IIa (AIR) Study Data of Buloxibutid for the Treatment of Idiopathic Pulmonary Fibrosis at ATS 2024
Shots:
- The P-IIa (AIR) study assessed the safety, tolerability & efficacy of buloxibutid (100mg, oral, BID) in treatment-naïve IPF patients for over 36wks.
- The study demonstrated improved lung function with a significant effect vs untreated patients experiencing a ~180mL decrease over 36wks. In the AIR trial, patients experienced an avg. FVC increase of 216mL from baseline to wk.36, nearly 400mL over the untreated patients (n=28) with improved FVC across all the subgroups and in patients treated since May 2023
- Based on this data, the company will advance buloxibutid into a P-IIb (ASPIRE) trial that will enroll patients treated with SoC (nintedanib) & those who are not, with the 1EP of change in FVC from baseline to 52wks.
Ref: Vicore |Image: Vicore
Related News:- Aileron Therapeutics Reports Cohort 1 Results from the P-Ib Study of LTI-03 for Idiopathic Pulmonary Fibrosis (IPF)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
